AUS
NZ
UK
CA
USA
IND
Highlights:
- Memphasys Ltd (ASX:MEM) has received recognition for its proprietary RoXsta antioxidant profiling system through a key scientific publication.
- The publication in the journal Antioxidants highlights RoXsta's ability to profile oxidative stress across human and animal samples effectively.
- RoXsta’s potential applications span reproductive health, livestock management, and broader clinical diagnostics.
Memphasys Ltd (ASX:MEM) has achieved a significant milestone with its proprietary RoXsta antioxidant profiling system gaining recognition in a recent manuscript published in the esteemed journal Antioxidants. The publication, titled A Comparative Analysis of the Antioxidant Profiles Generated by the RoXsta System for Diverse Biological Fluids, underscores the system’s scientific robustness and commercial potential.
The manuscript was co-authored by Laureate Professor John Aitken, Memphasys’ scientific director, alongside researchers from the University of Newcastle. It delves into the RoXsta system’s ability to accurately measure oxidative stress, a condition resulting from an imbalance between reactive oxygen species (ROS) and antioxidants. Oxidative stress is implicated in various health conditions, including infertility, cardiovascular disease, neurodegenerative disorders, and cancer.
The RoXsta system is designed to provide precise antioxidant profiling through its advanced diagnostic capabilities. It evaluates key parameters such as the ability to scavenge free radicals, suppress free radical formation, and neutralize harmful peroxides. This comprehensive approach makes RoXsta a valuable tool in identifying and managing oxidative stress-related challenges.
The publication highlights RoXsta’s performance in assessing oxidative stress across diverse biological samples, showcasing its relevance in both human and animal health applications. By bridging gaps in oxidative stress management, the system opens new opportunities for diagnostic and therapeutic advancements in reproductive health, clinical settings, and livestock industries.
David Ali, managing director and CEO of Memphasys, emphasized the transformative potential of RoXsta, stating that its capabilities strengthen Memphasys’ leadership in reproductive health while paving the way for broader applications across various industries. Ali remarked that RoXsta’s scalable design positions it as a multi-industry solution capable of addressing critical gaps in oxidative stress profiling and management.
The recognition from a prestigious journal adds to Memphasys’ growing credibility in the global scientific and medical community. RoXsta’s integration into diverse sectors demonstrates its adaptability and innovative edge, potentially establishing Memphasys as a leader in antioxidant profiling technology.
With oxidative stress being a key factor in numerous health conditions, the advancement of tools like RoXsta is expected to play a pivotal role in improving health outcomes and advancing research across multiple domains. Memphasys continues to explore new opportunities for RoXsta’s application, reinforcing its commitment to innovation and excellence in oxidative stress management.
